Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

导出原文传递

翻译打印收藏纠错

作者： Hayashi, Hideyuki ^[1] ; Kohno, Takashi ^[2] ; Ueno, Hideki ^[3] ; Hiraoka, Nobuyoshi ^[4] ; Kondo, Shunsuke ^[5] ; Saito, Motonobu ^[6] ; Shimada, Yoko ^[7] ; Ichikawa, Hitoshi ^[8] ; Kato, Mamoru ; Shibata, Tatsuhiro ; Morizane, Chigusa ; Sakamoto, Yasunari ; Shimada, Kazuaki ; Komatsu, Yoshito ; Sakamoto, Naoya ; Okusaka, Takuji

作者单位： Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan ^[1] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan ^[2] Natl Canc Ctr, Res Inst, Div Canc Genom, Tokyo, Japan ^[3] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Surg, Tokyo, Japan ^[4] Hokkaido Univ, Dept Canc Chemotherapy, Hosp Canc Ctr, Sapporo, Hokkaido, Japan ^[5] Natl Canc Ctr, Res Inst, Div Genome Biol, Tokyo, Japan ^[6] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan ^[7] Natl Canc Ctr, Res Inst, Div Genet, Tokyo, Japan ^[8]

关键词 clinical sequencing driver mutation genomic biomarker next-generation sequencer precision medicine

发布时间 2018-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交